PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026ChemistrySelect0 citationsOpen Access

Biotin‐Modified Boron‐Doped Carbon Dots as a Targeted Platform for Boron Neutron Capture Therapy

View Full Paper
GYGuohua YangZYZhiyuan YangYZYingyu Zhang

Key Points

  • To develop a novel platform for boron neutron capture therapy (BNCT) using biotin-derived boron-doped carbon dots.
  • Synthesis of biotin-derived boron-doped carbon dots (Bio-CDs) from biotin and boric acid (10B)
  • In vitro studies to assess tumor-targeting and BNCT efficacy
  • In vivo studies to evaluate safety and pharmacokinetics
  • Bio-CDs showed exceptionally high boron loading and strong tumor-targeting capability
  • In vitro and in vivo studies confirmed superior BNCT efficacy with negligible systemic toxicity
  • Bio-CDs demonstrated favorable biocompatibility and scalable synthesis properties

Abstract

ABSTRACT Boron neutron capture therapy (BNCT) is a promising cancer treatment strategy, yet its clinical application is hindered by the lack of efficient boron delivery agents. Herein, we developed biotin‐derived boron‐doped carbon dots (Bio‐CDs) as a novel multifunctional nanotherapeutic platform for targeted BNCT. Bio‐CDs were synthesized using biotin as the carbon source and boric acid ( 10 B) as the boron donor. The resulting Bio‐CDs demonstrated exceptionally high boron loading, excellent water dispersibility, and strong biotin receptor‐mediated tumor‐targeting capability. In vitro and in vivo studies confirmed superior BNCT efficacy with negligible systemic toxicity. Furthermore, the Bio‐CDs exhibited favorable pharmacokinetic properties, biocompatibility, and scalable synthesis from readily available materials. This multifunctional platform integrates high boron content, active targeting, and favorable biosafety, offering a scalable and clinically translatable solution for precision BNCT. The development of Bio‐CDs provides a new strategy for overcoming limitations of existing boron agents and advancing the clinical utility of BNCT in cancer therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/6980fde8c1c9540dea80fa16https://doi.org/10.1002/slct.202504889
Ask AI
Helpful
Bookmark
Share
View Full Paper